PA PQC
Pennsylvania Perinatal
Quality Collaborative
Pennsylvania Perinatal
Quality Collaborative
The PA PQC is working to reduce maternal mortality and improve care for pregnant and postpartum women and newborns.
The PA PQC is administered by the Jewish Healthcare Foundation and WHAMglobal, and it is affiliated with the Northeast PQC (NEPaPQC)
The Pennsylvania Perinatal Quality Collaborative (PA PQC) was launched in April 2019, with funding from the Pennsylvania Department of Drug and Alcohol Programs and the Henry L. Hillman Foundation as an action arm of the Maternal Mortality Review Committee (MMRC). Please see the reports, “Pennsylvania Maternal Mortality Review (2021 Report) and Pregnancy-Associated Deaths in Pennsylvania (2013-2018),” about the causes of deaths. Over 60 birth sites and NICUs and over 10 health plans across the Commonwealth are actively identifying perinatal processes that need to be improved and quickly adopting best practices to achieve the common aims.
The focus areas for 2022 include maternal substance use (including Opioid Use Disorder), substance-exposed newborns (including Neonatal Abstinence Syndrome, immediate postpartum long-acting reversible contraception (LARC), perinatal depression screening and follow-up (MOMD), and severe hypertension (PA AIM). Each focus area includes strategies and goals to reduce racial/ethnic disparities.
The PA PQC is inviting all the PA PQC health care teams to express interest in the 2022 priorities and initiatives via this survey by Monday, January 31. This is an informal expression of interest to help the PA PQC gain an updated understanding of how each PA PQC health care team will be prioritizing their PA PQC quality improvement work in 2022. This expression of interest survey is also an opportunity to ask questions or provide comments about the PA PQC 2022 initiatives and priorities. The more formal recruitment and engagement period will conclude by March 14.
The focus areas for 2022 include maternal substance use (including Opioid Use Disorder), substance-exposed newborns (including Neonatal Abstinence Syndrome, immediate postpartum long-acting reversible contraception (LARC), perinatal depression screening and follow-up (MOMD), and severe hypertension (PA AIM). Each focus area includes strategies and goals to reduce racial/ethnic disparities.
The PA PQC is inviting all the PA PQC health care teams to express interest in the 2022 priorities and initiatives via this survey by Monday, January 31. This is an informal expression of interest to help the PA PQC gain an updated understanding of how each PA PQC health care team will be prioritizing their PA PQC quality improvement work in 2022. This expression of interest survey is also an opportunity to ask questions or provide comments about the PA PQC 2022 initiatives and priorities. The more formal recruitment and engagement period will conclude by March 14.
Work Groups & Advisory
The PA PQC was created in 2019 when over 140 people from all the regions of the Commonwealth worked together to standup the PA PQC through an Advisory Group and a series of work groups on maternal OUD, NAS, and maternal mortality. The members represented State agencies, providers, health system associations, provider associations, health plans, community-based organizations, researchers, foundations, quality improvement collaboratives, and advocates. To position the PA PQC to expand its focus from OUD to Substance Use Disorders (SUD) and from NAS to Substance-Exposed Newborns (SEN), the PA PQC is re-convened statewide Work Groups to update its Driver Diagrams and quality measures for maternal SUD and SEN.